Bipolar Disorder (2018) |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
Bipolar Disorder or Schizophrenia |
0.91 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RASIP1 TMEM258 |
Intelligence (Savage-Jansen 2018) |
1.12 |
5 |
0 |
0.0 |
-0.53 |
2.8e-01 |
AMIGO1 DDX56 HPR TMED4 TMEM258 |
Alzheimer’s Disease (in mother) |
11.18 |
12 |
11 |
24.4 |
0.56 |
4.5e-02 |
APOC1 APOE BCAM CEACAM16 CEACAM19 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF229 ZNF285 |
Alzheimer’s Disease (in father) |
6.11 |
8 |
5 |
11.1 |
0.46 |
2.6e-01 |
APOC1 APOE CEACAM19 GEMIN7 PVRL2 TOMM40 ZNF229 ZNF285 |
Alzheimer’s Disease (including proxy) |
23.41 |
12 |
12 |
26.7 |
0.53 |
4.4e-02 |
APOC1 APOE BCAM CEACAM16 CEACAM19 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF229 ZNF285 |
Crohns Disease (2017) |
1.23 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RASIP1 TMEM258 |
Irritable Bowel Disease (IBD) |
0.91 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
Reaction Time |
0.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 SMARCA4 |
Verbal and Numeric Reasoning (VNR) |
1.10 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 TMEM258 |
Breast Cancer |
0.86 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO SPTY2D1 |
Ovarian Cancer |
1.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CARM1 |
Coronary Artery Disease (CAD) |
4.89 |
4 |
1 |
2.2 |
0.63 |
2.5e-01 |
ALDH2 BUD13 PSRC1 ZNF259 |
Crohns Disease (2012) |
1.14 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
DOCK7 RASIP1 TMEM258 |
Fasting Glucose |
1.49 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM258 |
HbA1C |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO |
HDL Cholesterol |
17.14 |
13 |
9 |
20.0 |
-0.46 |
9.9e-02 |
APOB APOC1 BUD13 C6orf106 CARM1 CETP HS1BP3 PSRC1 PVRL2 SORT1 TMEM258 TOMM40 ZNF259 |
Primary Biliary Cirrhosis |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Schizophrenia (2014) |
0.79 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DDX56 |
Triglycerides |
17.62 |
14 |
12 |
26.7 |
0.42 |
1.3e-01 |
APOB APOC1 APOE ATP13A1 BUD13 CETP DOCK7 HPR HS1BP3 PAFAH1B2 PCSK7 PVRL2 TMEM258 ZNF259 |
Blood Eosinophil Count |
2.87 |
15 |
10 |
22.2 |
-0.18 |
5.0e-01 |
ABO ALDH2 APOC1 APOE BCAM BUD13 CARM1 DCPS HNF1A PAFAH1B2 PVRL2 SMARCA4 TMEM258 TOMM40 ZNF259 |
Blood Platelet Count |
2.69 |
31 |
28 |
62.2 |
-0.51 |
1.4e-03 |
ABO ALDH2 APOC1 ATP13A1 BLOC1S3 BUD13 C6orf106 CARM1 CTB-179K24.3 DDX56 DOCK7 EVI5 GEMIN7 GSTM1 HMGCR HNF1A HP HPR KLC3 LDLRAP1 PAFAH1B2 PCSK7 PVR RASIP1 TMED4 TMEM258 TMEM50A TOMM40 ZHX3 ZNF259 ZNF285 |
Blood Red Count |
3.25 |
20 |
11 |
24.4 |
-0.34 |
1.4e-01 |
ABCG5 ABO ALDH2 AMIGO1 ATP13A1 C6orf106 DDX56 EFCAB13 HNF1A HP HPR HS1BP3 KLC3 MKRN2 PCSK7 PVRL2 SDF2 TMED4 TMEM258 ZHX3 |
Blood White Count |
2.13 |
16 |
9 |
20.0 |
-0.35 |
1.5e-01 |
ABO ALDH2 APOC1 APOE ATP13A1 CARM1 CETP EVI5 NYNRIN PAFAH1B2 PVR PVRL2 SMARCA4 ST3GAL4 STXBP3 TMEM258 |
Heel T-Score |
1.07 |
14 |
6 |
13.3 |
-0.58 |
2.4e-02 |
ABO ATP13A1 DOCK7 EVI5 HP LDLRAP1 MKRN2 PSRC1 SDF2 SORT1 TMEM258 TMEM50A USP24 ZHX3 |
BMI |
1.25 |
8 |
4 |
8.9 |
-0.49 |
2.1e-01 |
AMIGO1 C6orf106 CEACAM16 EVI5 HMGCR HPR KANK2 SDF2 |
Height |
1.67 |
28 |
20 |
44.4 |
-0.43 |
1.4e-02 |
ABCG5 ABO ALDH2 AMIGO1 APOC1 APOE ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK GEMIN7 KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SLC22A1 SMARCA4 SORT1 SPC24 SPTY2D1 ST3GAL4 TMEM258 TMEM50A ZNF229 ZNF259 |
Waist Hip Ratio (WHR) |
1.60 |
10 |
4 |
8.9 |
0.59 |
4.2e-02 |
APOC1 APOE ATP13A1 C6orf106 CARM1 KANK2 MKRN2 RASIP1 SMARCA4 ZHX3 |
Systolic Blood Pressure |
1.43 |
8 |
3 |
6.7 |
0.08 |
8.6e-01 |
ALDH2 APOC1 APOE PAFAH1B2 PCSK7 RASIP1 SMARCA4 TOMM40 |
Allergy or Eczema |
1.26 |
4 |
1 |
2.2 |
0.82 |
1.8e-01 |
ABO ALDH2 C6orf106 PVRL2 |
Cardiovascular Disease |
5.43 |
27 |
17 |
37.8 |
0.89 |
2.5e-11 |
ALDH2 APOB APOE BCAM BUD13 DDX56 DOCK7 EFCAB13 FRK HMGCR HNF1A HPR MKRN2 NPC1L1 PAFAH1B2 PCSK7 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TMED4 TOMM40 ZNF229 ZNF259 ZNF285 |
Hypothyroidism (self reported) |
2.52 |
4 |
3 |
6.7 |
0.23 |
7.1e-01 |
ALDH2 DDX56 RASIP1 TMEM258 |
Respiratory disease |
1.58 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO BLOC1S3 TMEM258 |
Type 2 Diabetes (T2D) (2018) |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 |
Lung FEV1/FVC ratio |
1.22 |
6 |
4 |
8.9 |
0.14 |
7.9e-01 |
C6orf106 EVI5 HP PSRC1 RASIP1 SORT1 |
Lung FVC |
0.59 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO C6orf106 PVRL2 |
Neuroticism |
0.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 |
Chronotype (morning person) |
1.24 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 AMIGO1 ZNF285 |
Hair Pigment |
0.17 |
6 |
3 |
6.7 |
-0.16 |
7.3e-01 |
ALDH2 EFCAB13 HS1BP3 MKRN2 SMARCA4 TMEM258 |
Tanning |
0.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Hand grip strength (left) |
0.86 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Number of treatments/medications taken |
2.14 |
4 |
1 |
2.2 |
0.74 |
2.6e-01 |
ALDH2 PSRC1 SORT1 TMEM258 |
Average weekly spirits intake |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RASIP1 |
Relative age of first facial hair |
0.85 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf106 |
Systolic blood pressure, automated reading |
0.92 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 RASIP1 |
Angina |
3.36 |
4 |
2 |
4.4 |
0.99 |
4.4e-04 |
ABCG5 PSRC1 SORT1 SPC24 |
Medication: Metformin |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 |
Diabetes (mother) |
1.52 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 PVRL2 |
Pack years adult smoking proportion |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMED4 |
Impedance of leg (right) |
1.01 |
8 |
5 |
11.1 |
0.38 |
3.5e-01 |
ABO AMIGO1 ATP13A1 C6orf106 EVI5 HMGCR TMEM167B TMEM50A |
Leg fat-free mass (left) |
1.64 |
7 |
3 |
6.7 |
-0.45 |
3.1e-01 |
ALDH2 ATP13A1 C6orf106 CARM1 HMGCR SMARCA4 SPTY2D1 |
Trunk fat percentage |
1.13 |
6 |
3 |
6.7 |
-0.49 |
3.2e-01 |
C6orf106 FRK GSTM1 HMGCR HPR PVRL2 |
Hand grip strength (right) |
0.89 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf106 PVRL2 |
Fed-up feelings |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Taking other prescription medications |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Age when periods started (menarche) |
0.78 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
HNF1A RASIP1 |
Heel bone mineral density (BMD) T-score, automated (left) |
0.97 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO TMEM258 |
High blood pressure |
1.43 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 NPC1L1 RASIP1 |
Hayfever, allergic rhinitis or eczema |
1.24 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf106 PVRL2 |
Medication: Atenolol |
2.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Medication: Levothyroxine sodium |
2.33 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ALDH2 TMEM258 |
Sitting height |
1.17 |
15 |
4 |
8.9 |
-0.16 |
5.7e-01 |
ABCG5 ABO AMIGO1 ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK HPR KANK2 RASIP1 SPC24 SPTY2D1 TMEM258 |
Body mass index (BMI) |
1.20 |
6 |
3 |
6.7 |
-0.55 |
2.5e-01 |
C6orf106 EVI5 GSTM1 HMGCR HPR PVRL2 |
Impedance of leg (left) |
1.09 |
9 |
4 |
8.9 |
0.38 |
3.2e-01 |
ABO AMIGO1 ATP13A1 C6orf106 CARM1 EVI5 HMGCR TMEM167B TMEM50A |
Leg predicted mass (left) |
1.63 |
7 |
3 |
6.7 |
-0.45 |
3.1e-01 |
ALDH2 ATP13A1 C6orf106 CARM1 HMGCR SMARCA4 SPTY2D1 |
Trunk fat mass |
1.44 |
6 |
3 |
6.7 |
-0.48 |
3.3e-01 |
C6orf106 FRK GSTM1 HMGCR HPR PVRL2 |
Waist circumference |
1.30 |
4 |
2 |
4.4 |
-0.70 |
3.0e-01 |
C6orf106 EVI5 HMGCR PVRL2 |
Past tobacco smoking |
0.96 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 |
Had other major operations |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABCG5 |
Forced vital capacity (FVC) |
0.84 |
4 |
2 |
4.4 |
-0.27 |
7.3e-01 |
ABO C6orf106 PVRL2 SMARCA4 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.07 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO LDLRAP1 TMEM258 |
Mouth/teeth dental problems |
1.29 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
DOCK7 RASIP1 SDF2 |
Heart attack |
3.07 |
3 |
2 |
4.4 |
1.00 |
4.1e-03 |
PSRC1 SORT1 SPC24 |
Allergy |
1.45 |
4 |
1 |
2.2 |
-0.75 |
2.5e-01 |
ABO BLOC1S3 C6orf106 TMEM258 |
Diabetes (self-reported) |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 |
Medication: Simvastatin |
13.18 |
25 |
16 |
35.6 |
0.97 |
9.4e-18 |
ABCG5 ABO APOB ATP13A1 BCAM BUD13 CETP DOCK7 GEMIN7 GSTM1 HMGCR HPR NPC1L1 PAFAH1B2 PSRC1 PVRL2 RASIP1 RP5-1065J22.8 SMARCA4 SORT1 SPC24 TMEM258 TOMM40 ZHX3 ZNF259 |
Weight |
1.74 |
7 |
3 |
6.7 |
-0.42 |
3.5e-01 |
ALDH2 C6orf106 CARM1 GSTM1 HMGCR HPR SMARCA4 |
Impedance of arm (right) |
1.08 |
9 |
3 |
6.7 |
0.43 |
2.5e-01 |
AMIGO1 C6orf106 EFCAB13 EVI5 GEMIN7 HMGCR KANK2 SDF2 TMEM167B |
Arm fat percentage (right) |
1.06 |
6 |
3 |
6.7 |
-0.38 |
4.6e-01 |
ABO C6orf106 GSTM1 HMGCR HPR PVRL2 |
Trunk fat-free mass |
1.77 |
8 |
6 |
13.3 |
-0.53 |
1.4e-01 |
ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Hip circumference |
1.85 |
8 |
4 |
8.9 |
-0.36 |
3.4e-01 |
ALDH2 C6orf106 CARM1 GSTM1 HMGCR HPR RASIP1 SMARCA4 |
Alcohol intake versus 10 years previously |
1.32 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 RASIP1 |
Father's age at death |
1.91 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PSRC1 SORT1 |
Number of live births |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
Forced expiratory volume in 1-second (FEV1) |
0.92 |
4 |
2 |
4.4 |
-0.27 |
7.3e-01 |
ABO C6orf106 PVRL2 SMARCA4 |
Pulse rate |
1.61 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM258 |
Mouth/teeth dental problems: Dentures |
1.09 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RASIP1 |
Asthma |
1.56 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
BLOC1S3 SMARCA4 TMEM258 |
Medication: Cholesterol lowering |
16.01 |
28 |
18 |
40.0 |
0.97 |
4.8e-19 |
ABCG5 ABO APOB ATP13A1 BCAM BUD13 CEACAM16 CETP DOCK7 DYNC2LI1 GSTM1 HMGCR HNF1A HPR KANK2 NPC1L1 PAFAH1B2 PSRC1 PVRL2 RASIP1 RP5-1065J22.8 SMARCA4 SORT1 SPC24 TOMM40 ZHX3 ZNF229 ZNF259 |
Forced expiratory volume in 1-second (FEV1), Best measure |
0.98 |
4 |
2 |
4.4 |
-0.27 |
7.3e-01 |
ABO C6orf106 PVRL2 SMARCA4 |
Impedance of arm (left) |
1.08 |
8 |
2 |
4.4 |
0.01 |
9.8e-01 |
ALDH2 AMIGO1 EFCAB13 EVI5 FRK HMGCR KANK2 SDF2 |
Arm fat mass (right) |
1.38 |
4 |
2 |
4.4 |
-0.82 |
1.8e-01 |
C6orf106 GSTM1 HMGCR HPR |
Trunk predicted mass |
1.78 |
8 |
6 |
13.3 |
-0.53 |
1.4e-01 |
ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Standing height |
1.68 |
19 |
13 |
28.9 |
-0.44 |
4.8e-02 |
ABCG5 ALDH2 AMIGO1 ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SMARCA4 SORT1 SPC24 SPTY2D1 TMEM258 |
Hair/balding pattern: Pattern 4 |
0.69 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM258 ZHX3 |
Birth weight of first child |
1.45 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 ATP13A1 HP |
Peak expiratory flow (PEF) |
1.05 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO C6orf106 RASIP1 |
Mouth/teeth dental problems: Bleeding gums |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SDF2 |
Blood clot in the leg (DVT) |
2.11 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Headache pain in last month |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Medication for cholesterol, blood pressure or diabetes |
5.88 |
13 |
6 |
13.3 |
-0.93 |
2.1e-06 |
APOB BUD13 CETP HMGCR HPR NPC1L1 PAFAH1B2 PSRC1 RASIP1 SORT1 SPC24 TOMM40 ZNF259 |
Hypothyroidism/myxoedema (self-reported) |
2.23 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ALDH2 TMEM258 |
Birth weight |
1.40 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 RASIP1 |
Chronic bronchitis/emphysema (mother) |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
BCAM |
Forced vital capacity (FVC), Best measure |
0.93 |
4 |
1 |
2.2 |
-0.25 |
7.5e-01 |
ABO C6orf106 PVRL2 SMARCA4 |
Body fat percentage |
1.11 |
6 |
3 |
6.7 |
-0.49 |
3.2e-01 |
BCAM C6orf106 GSTM1 HMGCR HPR PVRL2 |
Leg fat percentage (right) |
1.14 |
4 |
2 |
4.4 |
-0.76 |
2.4e-01 |
C6orf106 GSTM1 HMGCR KANK2 |
Arm fat-free mass (right) |
1.73 |
9 |
4 |
8.9 |
-0.52 |
1.2e-01 |
ALDH2 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Comparative body size at age 10 |
0.76 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RASIP1 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
Wheeze or whistling in the chest in last year |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
Qualifications: College or University degree |
0.92 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AMIGO1 DNAH11 KLC3 |
Medication for pain relief, constipation, heartburn |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EFCAB13 |
Medication: Blood pressure |
1.50 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 NPC1L1 |
Angina (self-reported) |
3.49 |
4 |
2 |
4.4 |
0.99 |
7.0e-04 |
ABCG5 PSRC1 SORT1 SPC24 |
Medication: Omeprazole |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH11 |
Mean time to correctly identify matches |
0.90 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 |
Heart disease (mother) |
2.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Whole body fat mass |
1.41 |
5 |
3 |
6.7 |
-0.48 |
4.1e-01 |
C6orf106 GSTM1 HMGCR HPR PVRL2 |
Leg fat mass (right) |
1.43 |
5 |
2 |
4.4 |
-0.36 |
5.6e-01 |
ALDH2 C6orf106 GSTM1 HMGCR HPR |
Arm predicted mass (right) |
1.72 |
9 |
3 |
6.7 |
-0.51 |
1.3e-01 |
ALDH2 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Pulse rate, automated reading |
1.68 |
4 |
2 |
4.4 |
-0.09 |
9.1e-01 |
C6orf106 KANK2 SORT1 TMEM258 |
Alcohol intake frequency. |
0.79 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RASIP1 |
Comparative height size at age 10 |
1.55 |
14 |
5 |
11.1 |
-0.41 |
1.2e-01 |
ALDH2 ATP13A1 C6orf106 DCPS EVI5 HNF1A KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SORT1 SPC24 SPTY2D1 |
Overall health rating |
0.91 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf106 |
Medication: Aspirin |
2.82 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PSRC1 SORT1 |
Hypertension (Self-reported) |
1.35 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ALDH2 RASIP1 |
Illnesses of father: Heart disease |
3.82 |
5 |
2 |
4.4 |
0.98 |
6.4e-04 |
NPC1L1 PSRC1 SORT1 SPC24 ST3GAL4 |
Smoking status: Previous |
1.23 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 |
Forced expiratory volume in 1-second (FEV1), predicted |
1.57 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf106 |
Whole body fat-free mass |
1.73 |
10 |
5 |
11.1 |
-0.49 |
1.2e-01 |
ALDH2 ATP13A1 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Leg fat-free mass (right) |
1.64 |
6 |
3 |
6.7 |
-0.42 |
4.1e-01 |
ALDH2 ATP13A1 C6orf106 HMGCR SMARCA4 SPTY2D1 |
Arm fat percentage (left) |
1.09 |
6 |
3 |
6.7 |
-0.40 |
4.4e-01 |
ABO C6orf106 GSTM1 HMGCR HPR PVRL2 |
Mood swings |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMIGO1 |
Diabetes diagnosed by doctor |
1.30 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 ATP13A1 |
Medication for cholesterol |
3.39 |
7 |
1 |
2.2 |
-0.93 |
7.0e-04 |
ALDH2 DOCK7 HMGCR PSRC1 PVRL2 RASIP1 SORT1 |
Back pain experienced in last month |
1.18 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOB C6orf106 |
Asthma (self-reported) |
1.56 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO BLOC1S3 TMEM258 |
Osteoarthritis (self-reported) |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMARCA4 |
Medication: Aspirin |
3.01 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PSRC1 SORT1 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Whole body water mass |
1.71 |
10 |
5 |
11.1 |
-0.49 |
1.3e-01 |
ALDH2 ATP13A1 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Leg predicted mass (right) |
1.63 |
6 |
3 |
6.7 |
-0.42 |
4.0e-01 |
ALDH2 ATP13A1 C6orf106 HMGCR SMARCA4 SPTY2D1 |
Arm fat mass (left) |
1.41 |
4 |
2 |
4.4 |
-0.84 |
1.6e-01 |
C6orf106 GSTM1 HMGCR HPR |
Number of self-reported non-cancer illnesses |
2.17 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 RASIP1 |
Average weekly champagne plus white wine intake |
1.08 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM258 |
Medication: Blood pressure |
1.32 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 RASIP1 |
Supplements: Fish oil (including cod liver oil) |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM258 |
High cholesterol (Self-reported) |
27.45 |
47 |
35 |
77.8 |
0.97 |
2.1e-34 |
ABCG5 ABO AMIGO1 APOB APOC1 ATP13A1 BCAM BUD13 CARM1 CEACAM16 CEACAM19 CETP DDX56 DNAH11 DOCK7 EFCAB13 GSTM1 HMGCR HNF1A HP HPR HS1BP3 KANK2 LDLRAP1 MKRN2 N4BP2L1 NPC1L1 NYNRIN PAFAH1B2 PCSK7 PSRC1 PVR PVRL2 RASIP1 RP5-1065J22.8 SLC22A1 SMARCA4 SORT1 SPC24 TMED4 TMEM258 TOMM40 USP24 ZHX3 ZNF229 ZNF259 ZNF285 |
Medication: Bendroflumethiazide |
0.87 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RASIP1 |
Medication: Atorvastatin |
11.63 |
21 |
11 |
24.4 |
0.94 |
1.2e-11 |
ABO APOB ATP13A1 BCAM BUD13 CARM1 DOCK7 EFCAB13 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TOMM40 ZNF229 ZNF259 ZNF285 |
Ever smoked |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Basal metabolic rate |
1.75 |
9 |
5 |
11.1 |
-0.46 |
2.1e-01 |
ALDH2 ATP13A1 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Leg fat percentage (left) |
1.13 |
5 |
2 |
4.4 |
-0.60 |
2.9e-01 |
BCAM C6orf106 GSTM1 HMGCR KANK2 |
Arm fat-free mass (left) |
1.74 |
8 |
4 |
8.9 |
-0.51 |
1.6e-01 |
ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |
Number of operations (self-reported) |
0.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABCG5 |
Irritability |
1.01 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP13A1 EFCAB13 TMEM258 |
Diastolic blood pressure, automated reading |
1.35 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO ALDH2 |
Myopia |
1.61 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf106 KANK2 TMEM258 |
Vascular/heart problems diagnosed by doctor |
1.59 |
4 |
1 |
2.2 |
0.50 |
5.0e-01 |
ALDH2 EVI5 NPC1L1 RASIP1 |
Cholesterol lowering medication |
13.87 |
28 |
16 |
35.6 |
0.96 |
7.2e-18 |
ABCG5 ABO APOB BCAM BUD13 DDX56 DOCK7 HMGCR HNF1A HPR KANK2 N4BP2L1 NPC1L1 PAFAH1B2 PCSK7 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TMED4 TMEM167B TOMM40 ZHX3 ZNF229 ZNF259 ZNF285 |
Medication: Omeprazole (e.g. Zanprol) |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH11 |
Pain experienced in last month |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Heart attack/myocardial infarction (self-reported) |
3.08 |
3 |
2 |
4.4 |
1.00 |
4.1e-03 |
PSRC1 SORT1 SPC24 |
Deep venous thrombosis (DVT) (self-reported) |
2.00 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Pack years of smoking |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMED4 |
Impedance of whole body |
0.97 |
6 |
3 |
6.7 |
0.89 |
1.6e-02 |
AMIGO1 C6orf106 EVI5 FRK HMGCR TMEM167B |
Leg fat mass (left) |
1.41 |
4 |
2 |
4.4 |
-0.86 |
1.4e-01 |
C6orf106 GSTM1 HMGCR HPR |
Arm predicted mass (left) |
1.80 |
8 |
4 |
8.9 |
-0.53 |
1.4e-01 |
ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1 |